Edition:
India

Acer Therapeutics Inc (ACER.OQ)

ACER.OQ on NASDAQ Stock Exchange Capital Market

2.54USD
10:21pm IST
Change (% chg)

$-0.10 (-3.79%)
Prev Close
$2.64
Open
$2.61
Day's High
$2.61
Day's Low
$2.46
Volume
2,787
Avg. Vol
75,938
52-wk High
$7.23
52-wk Low
$1.08

Latest Key Developments (Source: Significant Developments)

Acer Therapeutics Reports Q2 Loss Per Share $0.56
Friday, 14 Aug 2020 

Aug 13 (Reuters) - Acer Therapeutics Inc ::ACER THERAPEUTICS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.56.Q2 EARNINGS PER SHARE ESTIMATE $-0.38 -- REFINITIV IBES DATA.  Full Article

Acer Therapeutics Reports Q1 Loss Per Share Of $0.49
Friday, 15 May 2020 

May 14 (Reuters) - Acer Therapeutics Inc ::ACER THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.49.Q1 EARNINGS PER SHARE ESTIMATE $-0.40 -- REFINITIV IBES DATA.ENDED Q1 WITH $7.0 MILLION IN CASH AND CASH EQUIVALENTS.  Full Article

Acer Therapeutics Receives Formal Dispute Resolution Request (Fdrr) Response From FDA's Office Of New Drugs
Thursday, 19 Mar 2020 

March 18 (Reuters) - Acer Therapeutics Inc ::ACER THERAPEUTICS INC - RECEIVES FORMAL DISPUTE RESOLUTION REQUEST (FDRR) RESPONSE FROM FDA'S OFFICE OF NEW DRUGS.ACER THERAPEUTICS - FDA'S OFFICE OF NEW DRUGS HAS DENIED ACER'S APPEAL OF COMPLETE RESPONSE LETTER IN RELATION TO NDA FOR EDSIVO.ACER THERAPEUTICS - EVALUATING POSSIBLE NEXT STEPS WITH GOAL OF RESUBMISSION OF EDSIVO NDA.ACER THERAPEUTICS - BELIEVES CASH POSITION WILL BE SUFFICIENT TO FUND ITS CURRENT OPERATIONS THROUGH END OF 2020, EXCLUDING SOME ACTIVITIES.  Full Article

Acer Therapeutics Reports Third Quarter Results
Thursday, 14 Nov 2019 

Nov 13 (Reuters) - Acer Therapeutics Inc ::ACER THERAPEUTICS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.52.Q3 EARNINGS PER SHARE ESTIMATE $-0.57 -- REFINITIV IBES DATA.ACER THERAPEUTICS - COMPLETED EDSIVO TYPE A MEETING FOLLOWING RECEIPT OF COMPLETE RESPONSE LETTER, EVALUATING PLANS TO APPEAL DECISION.ENDED Q3 WITH $16.1 MILLION IN CASH AND CASH EQUIVALENTS.ACER THERAPEUTICS - BELIEVES CASH POSITION TO BE SUFFICIENT TO FUND CURRENT OPERATING, CAPITAL REQUIREMENTS THROUGH 2020-END.  Full Article

Acer Therapeutics Reports Second Quarter Loss Per Share $1.09
Wednesday, 14 Aug 2019 

Aug 13 (Reuters) - Acer Therapeutics Inc ::ACER THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $1.09.Q2 EARNINGS PER SHARE ESTIMATE $-0.78 -- REFINITIV IBES DATA.CASH AND CASH EQUIVALENTS WERE $23.5 MILLION AS OF JUNE 30, 2019, COMPARED TO $41.7 MILLION AS OF DECEMBER 31, 2018.  Full Article

Acer Therapeutics Sees Charge Of About $1.5 Million Associated With Workforce Reduction In Q2 Of 2019.
Friday, 5 Jul 2019 

July 5 (Reuters) - Acer Therapeutics Inc ::ACER THERAPEUTICS INC - SEES SEVERANCE-RELATED CHARGE OF ABOUT $1.5 MILLION ASSOCIATED WITH WORKFORCE REDUCTION IN Q2 OF 2019..  Full Article

Acer Therapeutics Reorganizes; Headcount Reduced To 19 Employees
Friday, 5 Jul 2019 

July 5 (Reuters) - Acer Therapeutics Inc ::ACER THERAPEUTICS INC - HEADCOUNT HAS BEEN REDUCED FROM 48 TO 19 EMPLOYEES.ACER THERAPEUTICS INC - RESTRUCTURING EXPECTED TO EXTEND CASH RUNWAY THROUGH END OF 2020.ACER THERAPEUTICS INC - ACER PLANS TO DISCUSS EDSIVO CRL WITH FDA AND WILL CONTINUE TO ADVANCE ADDITIONAL PIPELINE PRODUCTS.ACER THERAPEUTICS INC - EXPECTS TO INITIATE A PIVOTAL BRIDGING STUDY IN Q4 2019 OF ACER-001 FOR UREA CYCLE DISORDERS (UCDS).ACER THERAPEUTICS - EXPECTS TO DISCLOSE SPECIFIC INDICATIONS FOR DEVELOPMENT OF OSANETANT IN LATE JULY 2019.ACER THERAPEUTICS INC - PRE-COMMERCIAL ACTIVITIES OF EDSIVO (CELIPROLOL) HAVE BEEN HALTED..ACER THERAPEUTICS INC - TO INITIATE A CLINICAL STUDY BY MID-2020 TO EVALUATE PHARMACOKINETICS, PHARMACODYNAMICS AND SAFETY OF OSANETANT .  Full Article

Acer Therapeutics Gets CRL From FDA For Use Of Edsivo In Veds Patients
Tuesday, 25 Jun 2019 

June 25 (Reuters) - Acer Therapeutics Inc ::ACER THERAPEUTICS RECEIVES COMPLETE RESPONSE LETTER FROM U.S. FDA FOR USE OF EDSIVO™ (CELIPROLOL) IN VEDS PATIENTS.ACER THERAPEUTICS - PLANS TO REQUEST A MEETING TO DISCUSS THE FDA’S RESPONSE.ACER THERAPEUTICS - EXPECT TO RESPOND TO THE FDA IN THE THIRD QUARTER OF THIS YEAR.ACER THERAPEUTICS-CRL STATES ADEQUATE, WELL-CONTROLLED TRIAL WILL BE NEEDED TO SEE IF CELIPROLOL REDUCES RISK OF CLINICAL EVENTS IN PATIENTS WITH VEDS.  Full Article

Acer Therapeutics Reports Q1 Loss Per Share $0.79
Wednesday, 15 May 2019 

May 14 (Reuters) - Acer Therapeutics Inc ::ACER THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.79.Q1 EARNINGS PER SHARE ESTIMATE $-0.82 -- REFINITIV IBES DATA.ENDED Q1 WITH $31.8 MILLION IN CASH AND CASH EQUIVALENTS.BELIEVES CASH AND CASH EQUIVALENTS SUFFICIENT TO FUND ITS CURRENT OPERATING AND CAPITAL REQUIREMENTS INTO FIRST HALF OF 2020.  Full Article

Acer Therapeutics Announces FDA Acceptance Of NDA And Priority Review For EDSIVO For The Treatment Of vEDS
Wednesday, 26 Dec 2018 

Dec 26 (Reuters) - Acer Therapeutics Inc ::ACER THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF NDA AND PRIORITY REVIEW FOR EDSIVO™ FOR THE TREATMENT OF VEDS.ACER THERAPEUTICS INC - FDA ASSIGNED A PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE OF JUNE 25, 2019.ACER THERAPEUTICS INC - FDA ALSO GRANTED A PRIORITY REVIEW OF NDA.  Full Article

BRIEF-Acer Therapeutics Inc Anticipates Submitting ACER-001 NDA In H1 2021

* ACER THERAPEUTICS ANNOUNCES ADMINISTRATION OF ACER-001 IN A FASTED STATE INCREASED SYSTEMIC EXPOSURE OF PHENYLBUTYRATE IN HEALTHY VOLUNTEER FOOD EFFECT STUDY